Skip to main content
SpringerLink
Log in

Molecular Prognostic Markers of Lung Cancer

  • Chapter
  • First Online:
Molecular Pathology of Lung Cancer

Part of the book series: Molecular Pathology Library ((MPLB,volume 6))

Abstract

Many biomarkers have been reported to be independent prognostic factors in patients with lung cancer. KRAS mutations have been frequently associated with negative prognosis, although recent adjuvant chemotherapy trials filed to demonstrate prognostic role of KRAS. Prognostic significance of ERCC1 is controversial, and IALT showed prolonged survival in ERCC1-negative tumors treated with adjuvant chemotherapy. Numerous gene expression studies have reported prognostic gene expression signatures, although reported data are very heterogenous. The most cited prognostic signatures include a 5-gene signature with DUSP6 (dual-specificity phosphatase 6), MMD (monocyte-to-macrophage differentiation-associated protein), STAT1 (signal transducer and activator of transcription 1), ERBB3 (v-erb b2 avian erythroblastic leukemia viral oncogene homolog 3), and LCK (lymphocyte specific protein tyrosine kinase) at the most significant prognostic genes in surgically resected NSCLC. The lung metagene model identified key metagenes such as BRAF, phosphatidylinositol 3′ quinase, TP53, and MYC signaling pathways as predictor of recurrence in early-stage lung adenocarcinoma. A 50-gene signature separated patients with stage I lung adenocarcinoma into low- and high-risk, and predicted survival. Recently, miRNA, a family of small, noncoding functional RNAs, was indicated as a potential prognostic marker. High hsa-mir-155 and low hsa-let-7a-2 expression correlated with poor survival in lung adenocarcinoma. Patients with a high expression of a signature of 5 miRNAs (let-7a, miR-221, miR-137, miR-372, miR-182) had increased relapse rate and shorter survival.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJ, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med. 1990;323(9):561–5.

    Article  PubMed  CAS  Google Scholar 

  2. Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2005;92(1):131–9.

    Article  PubMed  CAS  Google Scholar 

  3. Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol. 2010;28(1):29–34.

    Article  PubMed  CAS  Google Scholar 

  4. Altaha R, Liang X, Yu JJ, Reed E. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med. 2004;14(6):959–70.

    PubMed  CAS  Google Scholar 

  5. Lord RVN, Brabender J, Gandara D, Alberola V, Camps C, Domine M, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002;8(7):2286–91.

    PubMed  CAS  Google Scholar 

  6. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, et al. DNA repair by ERCC1 in ­non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355(10):983–91.

    Article  PubMed  CAS  Google Scholar 

  7. Chen H-Y, Yu S-L, Chen C-H, Chang G-C, Chen C-Y, Yuan A, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 2007;356(1):11–20.

    Article  PubMed  CAS  Google Scholar 

  8. Singhal S, Miller D, Ramalingam S, Sun S-Y. Gene expression profiling of non-small cell lung cancer. Lung Cancer. 2008;60(3):313–24.

    Article  PubMed  Google Scholar 

  9. Beer DG, Kardia SLR, Huang C-C, Giordano TJ, Levin AM, Misek DE, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 2002;8(8):816–24.

    PubMed  CAS  Google Scholar 

  10. Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med. 2006;355(6):570–80.

    Article  PubMed  CAS  Google Scholar 

  11. Guo NL, Wan Y-W, Tosun K, Lin H, Msiska Z, Flynn DC, et al. Confirmation of gene expression-based prediction of survival in non-small cell lung cancer. Clin Cancer Res. 2008;14(24):8213–20.

    Article  PubMed  CAS  Google Scholar 

  12. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med. 2008;14(8): 822–7.

    Article  PubMed  CAS  Google Scholar 

  13. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9(3):189–98.

    Article  PubMed  CAS  Google Scholar 

  14. Yu S-L, Chen H-Y, Chang G-C, Chen C-Y, Chen H-W, Singh S, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell. 2008;13(1):48–57.

    Article  PubMed  CAS  Google Scholar 

  15. Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, Fan H, et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 2009;69(14):5776–83.

    Article  PubMed  CAS  Google Scholar 

  16. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. Reduced expression of the let-7 microRNAs in human lung cancers in ­association with shortened postoperative survival. Cancer Res. 2004;64(11):3753–6.

    Article  PubMed  CAS  Google Scholar 

  17. Inamura K, Togashi Y, Nomura K, Ninomiya H, Hiramatsu M, Satoh Y, et al. let-7 microRNA expression is reduced in bronchioloalveolar carcinoma, a non-invasive carcinoma, and is not correlated with prognosis. Lung Cancer. 2007;58(3):392–6.

    Article  PubMed  Google Scholar 

  18. Dacic S, Kelly L, Shuai Y, Nikiforova MN. miRNA expression profiling of lung adenocarcinomas: correlation with mutational status. Mod Pathol. 2010;23(12): 1577–82.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

    Sanja Dacic MD, PhD

Authors
  1. Sanja Dacic MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sanja Dacic MD, PhD .

Editor information

Editors and Affiliations

  1. , Department of Pathology, The Methodist Hospital, 6565 Fannin Street, Houston, 77030, Texas, USA

    Philip T. Cagle

  2. Health Science Center at Tyler, Department of Pathology, The University of Texas, 11937 US Highway 271, Tyler, 75708, Texas, USA

    Timothy Craig Allen

  3. , Department of Pathology, Mount Sinai Medical Center, 1 Gustave L. Levy Place, New York, 10029, New York, USA

    Mary Beth Beasley

  4. , Department of Pathology, Brigham and Women's Hospital, 75 Francis St., Boston, 02115, Massachusetts, USA

    Lucian R. Chirieac

  5. Medical Center, Department of Pathology, University of Pittsburgh, 200 Lothrop St. - PUH C608, Pittsburgh, 15213, Pennsylvania, USA

    Sanja Dacic

  6. Medical Center, Department of Pathology &, Columbia University, 630 W. 168th Street VC-14-215, New York, 10032, New York, USA

    Alain C. Borczuk

  7. Medical School, Department of Pathology, Aberdeen University, Foresterhill, Aberdeen, Scotland, AB25 2ZD, United Kingdom

    Keith M. Kerr

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media New York

About this chapter

Cite this chapter

Dacic, S. (2012). Molecular Prognostic Markers of Lung Cancer. In: Cagle, P., et al. Molecular Pathology of Lung Cancer. Molecular Pathology Library, vol 6. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3197-8_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-3197-8_11

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-3196-1

  • Online ISBN: 978-1-4614-3197-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation